GleamWall
中文EN

ZOMDF Zomedica Corp.

Pharmaceutical Preparations · OTC · SEC CIK 1684144 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.3%
TTM net income YoY81.1%
TTM EPS YoY88.9%
Revenue 3-yr CAGR17.2%
Net income 3-yr CAGR—

Margins

Gross margin64.0%
Operating margin-45.4%
Net margin-41.4%
FCF margin-30.8%
EBITDA margin-40.0%

Returns

ROE-14.3%
ROA-13.0%
ROIC (approx.)-13.3%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets9.3%
Debt / equity0.00x
Current ratio6.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.90M$9.51M$8.80M$10.47M$8.10M$6.96M$6.50M$7.89M
Cost of revenue$3.85M$3.47M$3.31M$3.30M$2.66M$2.30M$2.09M$2.35M
Gross profit$6.04M$6.04M$5.48M$7.17M$5.44M$4.67M$4.41M$5.55M
R&D expense$1.20M$1.07M$1.15M$1.64M$1.78M$1.89M$1.85M$2.15M
SG&A expense$4.71M$5.38M$5.41M$6.17M$5.90M$6.16M$6.26M$6.29M
Operating income-$3.42M-$4.08M-$4.90M-$5.16M-$6.61M-$8.04M-$64.55M-$8.16M
Pretax income-$3.16M-$3.74M-$4.50M-$4.74M-$6.14M-$7.39M-$63.87M-$7.42M
Income tax$9,000$26,000$39,000-$214,000-$19,000$12,000-$57,000-$221,000
Net income-$3.17M-$3.77M-$4.53M-$4.53M-$6.12M-$7.40M-$63.81M-$7.19M
EBITDA-$2.89M-$3.56M-$4.38M-$4.64M-$6.10M-$7.53M-$64.03M-$7.72M
EPS (basic)0.000.000.00—-0.01-0.01-0.07—
EPS (diluted)——0.00—-0.01-0.01-0.07—
Weighted avg. shares (diluted)————979.95M979.95M979.95M—
Balance sheet
Cash & equivalents$7.28M$7.19M$9.37M$9.02M$7.50M$8.13M$8.84M$7.02M
Receivables$6.79M$5.67M$4.43M$3.01M$3.14M$2.30M$1.57M$2.42M
Inventory$5.77M$6.05M$5.88M$5.54M$5.52M$5.67M$5.36M$5.06M
Current assets$55.44M$57.89M$60.03M$64.04M$64.69M$68.60M$73.22M$81.77M
PP&E, net$19.56M$20.04M$20.46M$20.91M$21.38M$21.86M$22.24M$24.59M
Goodwill———$0$0$0—$45.56M
Intangibles$36.65M$37.37M$37.98M$38.81M$40.10M$41.40M$42.77M$52.54M
Total assets$115.03M$118.15M$121.53M$127.04M$130.91M$136.47M$142.99M$207.36M
Current liabilities$9.10M$9.00M$8.56M$9.45M$8.43M$8.13M$7.41M$9.33M
Total liabilities$10.74M$10.86M$10.59M$11.64M$11.22M$11.12M$10.55M$11.70M
Shareholders' equity$104.28M$107.28M$110.94M$115.40M$119.69M$125.36M$132.44M$195.66M
Shares outstanding979.95M979.95M979.95M979.95M979.95M979.95M979.95M979.95M
Cash flow statement
Operating cash flow-$2.77M-$2.55M-$5.26M-$899,000-$4.66M-$5.44M-$6.65M-$4.53M
Capital expenditure$187,000$92,000$60,000$107,000$43,000$137,000$280,000$575,000
Free cash flow-$2.96M-$2.64M-$5.32M-$1.01M-$4.70M-$5.58M-$6.93M-$5.10M
Investing cash flow$2.84M$386,000$5.62M$2.45M$4.04M$4.68M$8.41M$1.92M
Financing cash flow———————$0
Depreciation & amortization$535,000$526,000$519,000$519,000$506,000$509,000$521,000$443,000
Stock-based compensation-$38,000$69,000$643,000$727,000$867,000$260,000$618,000$345,000

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.